Clareo Health | Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer
Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nantes University Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with metastatic melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma treated with nivolumab monotherapy
Patients whose nivolumab treatment was initiated between 2015 and 2020
Patients with health insurance
You may not be if
Patients whose nivolumab treatment initiated in 2017 in mg/kg has progressed to a fixed dose in the 1st year of treatment
Patients treated with nivolumab in the adjuvant setting for melanoma with lymph node involvement or metastatic disease and who have undergone complete resection (Approval in 2018 for this indication)
Patients whose nivolumab treatment has been initiated in 2018
